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The following Investment Committee paper focuses on a proposal for a leveraged buyout on Elekta AB, a key player in the global radiotherapy market. In fact, this paper
develops a set of value creation strategies, with special focus on Buy-and-Build, reflecting those strategies in a detailed operating model. Subsequently, a capital structure
is suggested by assessing past buyout transactions in the healthcare sector and by leveraging the bank case. Finally, the exit returns are estimated complying with
industry threshold and a range of exit strategies are analyzed. Moreover, exit options are compiled in order to fully maximize ELEKTA’s exit.
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Disclaimer: This Work Project was prepared by a group of students from Nova School of Business and Economics as the Master’s Thesis for the Master in Finance 
Program. We, hereby, pledge on our honor that the work presented is ours and that none dishonest method was used in its execution. Furthermore, we declare that this 
Work Project is intended to be used for academic purposes only. Therefore, we restrain ourselves from taking any responsibility from the wrong usage of the content 
presented, namely any investment or legal action taken grounded on it. 
This Work Project was developed using publicly available data and information provided by the company (i.e., annual reports, investor relations, presentations, etc.). The
sources of the information are disclosed when appropriated.
This Work Project is divided into three complementary parts. For an integral analysis of the Work Project please see the remaining two parts named “Power of Proton
Solutions in Radiotherapy Market” and “Mitigation of Structural Differences in Cancer Treatment ”
This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019) and Social Sciences




Elekta AB is a Swedish manufacturer of radiotherapy
medical equipment. Its products and aftermarket
services are sold to both public and private sector;
Its product portfolio consists of linear accelerators,
magnetic resonance imaging linear accelerators
(MR-Linacs), brachytherapy, oncology informatic
solutions (OIS) and neurosolutions;
Elekta provides a range of quality services that
include maintenance, updates, training, among
others;
With an emphasis in customization, Elekta has been
one of the main leaders in the radiotherapy market.
COMPANY PROFILE
Elekta seems to be an exciting investment opportunity yielding an investors’ return of 3.14x
DEAL RATIONALE
VALUE CREATION & EXIT AND RETURNS
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INDUSTRY PROFILE
Elekta is distinguished by its efficiency and has reached
a leading position in emerging markets
Strong Cash-Flow Generation
Brand Prestige and Market Leadership
Free Cash Flow generated by the company is robust
and has been stable over the past few years
Strategic value-adding acquisitions allowed Elekta to
become a key player in radiotherapy market
Acquisition history
Sizeable and Growing Market
Optimistic industry growth prospects, since cancer




Radiotherapy is one of the main types of cancer
treatment. With cancer incidence expected to
increase until 2040, significant investments have
been made in the oncology market;
Accordingly, the radiotherapy market is expected to
increase at a CAGR of 7.3% until 2029, from a $6.6B
value in 2019;
This growth will be mainly driven by innovations in the
sector (namely MR-Linacs and OIS), and the
increasing demand for radiotherapy, as 60% of
cancer patients are expected to need it.
4
o It is expected that the increase in revenues and the
improvement of EBITDA margin, will create SEK
50,629M of value;
o With the deleveraging effect, the investment will
generate SEK 57,500M of value.
o The fund will generate a combined return of 3.45x in
five years (IRR of 28.07%);
o Institutional investors and managers will have
returns of 3.14x and 136.1x respectively.
Financials 2020 2021F 2022F 2023F 2024F 2025F
Organic Sales 14,601 14,722 19,506 22,571 24,214 26,390
% growth - 1% 32% 16% 7% 9%
Org EBITDA 2,921 3,088 4,170 4,814 5,280 5,886
Inorg Sales N/A 0 3,134 4,839 5,584 6,018
% growth - - - 54% 15% 8%
HCG 0 0 3,134 3,302 3,887 4,144
IBA 0 0 0 1,537 1,697 1,874
Inorg EBITDA N/A 0 275 634 784 892
EBITDA 2,921 3,088 4,445 5,449 6,065 6,778
% mg 20% 21% 20% 20% 20% 21%





COMPANY OVERVIEW | PROFILE
o Founded in 1972, its headquarters are located
in Stockholm, Sweden. It has been listed in the
OMX Nordic Exchange since 1994 and currently
employs more than 4,000 people;
o ELEKTA is one of the key players in the global
radiotherapy market, providing radiotherapy
equipment in order to treat different types of
cancer and brain disorders;
o The company sells both to the public and
private sector (hospitals, private clinics) in more
than 120 countries;
o Elekta has a wide range of suppliers – 80%
of sourced products/services come from
approximately 450 suppliers. In some specific
products (MR Linac–Image) there is only one
supplier, which might increase the shortage risk;
o Its position in the value chain is as a medical
equipment manufacturer and software
provider, that has been distinguished by its
innovation and efficiency. It is also known by
customizing their products for each specific
client. The main activities of the production units
are assembly, testing and quality assurance;
COMPANY PROFILE RANGE OF PRODUCTS
Elekta is one of the key players in the global radiotherapy market (radiation therapy & radiosurgery)
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Offers leading solutions in both
radiotherapy treatment and
oncology informatics systems.














PIONEERS IN PRECISION RADIATION MEDICINE
Rank
% Margin
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Sources: Elekta’s Annual Report and Website
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COMPANY OVERVIEW | PRODUCT MIX
Elekta’s diversified product portfolio enables this company to thrive in the radiotherapy market
201720132008 2018
Sources: Elekta’s Annual Report and Website; Investor Presentation 2018
2003
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COMPANY OVERVIEW | GROWTH DRIVERS AND GEOGRAPHICAL BREAKDOWN
Securing improved financial performance as well as operational excellence 
PROFITABILITY DRIVERS
ELEKTA’S ACQUISITION HISTORY
o Elekta’s market share 40%
o Net Sales 31% 
o Solutions 72%
o Services 28%
o Elekta’s market share 43%
o Net Sales 38%
o Solutions 64%
o Services 36%
o Elekta’s market share 21%
o Net Sales 31%
o Solutions 44%
o Services 56%
North and South America EMEA APAC
o Expanding Product Portfolio i.e Brachy Solutions and MRI Linacs
gives access to more potential customers;
o Market need for cost-efficient and digitalized cancer care can be
exploit by Elekta, since it is a key player which provides high-quality
solutions and services;
o Its Precision Radiation Medicine - easier to use, improve patient
experience, increase workflow - can lead to strong customer’s
relationship, increasing clients’ long-term brand loyalty;
o Gross Margin and SG&A margin improvement by increasing the
efficiency in internal processes. Elekta wants to replicate its Harmony
Solution COGS reduction in the other innovative products already
provided, in order to improve its gross margin. By sharing services and
digitalization (remote assistance; remote conferences) it aims to reduce
its SG&A costs (COVID also helped in reducing travel expenses);
NeuromagPhilips Radiation 
Therapy Division 











2014/1520111972 20062005 20081997 2003 2018/20
$20M $75M €365M >SEK 178M
Linear Accelerators;        Oncology Informatics;        Stereotactic Radiosurgery;        Brachytherapy;      MR–Linear Accelerators  
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Market defined by innovative procedures
that will continue to play a major role in
cancer treatment.
EMEA
MARKET OVERVIEW | A BROADER PICTURE OF RADIOTHERAPY
RADIOTHERAPY MARKET AROUND THE WORLD
o The market is steadily growing in Western Europe due to increasing capacity and renovation of
equipment. Private Sector’s role plays an important role, but national programs are the main
responsible for funding cancer treatments, care and research;
o In Eastern Europe there is still a lack of infrastructure, but national services have been developing;
o In Middle East and Africa there is still a considerable lack of resources. However, increasing
awareness of the problems of cancer, the increasing demand in the Middle East and the
emergence of Turkey as a fast-growing market, make MEA a long-term attractive region.
AMERICAS
o North America market is characterized by a prominence of private providers that have
consolidated their position over the years, creating a competitive environment. 60% of North
American patients are treated with radiotherapy and there is increasing demand to renew existent
equipment;
o In South America there is a mix of public and private sector, existing inadequate accessibility to
public services;
o Nevertheless, the emergence of healthcare groups which are investing in radiotherapy clinics and
a need for modernization will drive the market forward in the next years.
APAC
o China is the most important market in the Asia-Pacific region, with the government incentivizing
the expansion of radiotherapy, both in capacity and renewing equipment;
o Japan has one of the biggest growth potential, as 70% of cancer patients do not receive
radiotherapy. Hong-Kong, Australia, Singapore and South Korea are also mature markets with
adequate levels of investment in radiotherapy;
o India also expects a long-term growth in radiotherapy demand. Currently, radiotherapy is more
prominent in the private-sector, but it in the long-term the public sector will increase its investment.




CAGR of 7.3%     
until 2029
Up to 60% of cancer patients need
radiotherapy solutions. However, around
half of them are unable to access it. The
different states of development between
regions are key determinants to access rates
to radiotherapy solutions.
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Sources: Elekta’s Annual Report and Website; Grandviewresearch
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MARKET OVERVIEW | COMPETITIVE LANDSCAPE
Pursuit of the best cost-effective solutions that
could offset structural differences between
countries and regions.
Constant search for innovation (e.g., current
pandemic enhanced the importance of remote
monitoring and maintenance).
Acquisitions and partnerships play a key
role on differentiation and market share
gains.
Elekta’s main competitor is Varian but emergent markets dominance could offset discrepancies 
MARKET COMPETITIVE DYNAMICS
5 FORCES OF PORTER
Attracting and retaining the most qualified
employees
Companies must ensure that their products
are reimbursed as much as possible.
Protection of patients to maintain value














1 Competition in the industry       ►
2 Potential of new entrants           ►
3 Power of suppliers                     ►
4 Power of customers                  ►
5 Threat of substitute products   ►
➢ Competition based on R&D investment, cost-
efficiency and after-market services;
➢ Only Varian has an overlap with Elekta’s product
portfolio but there are significant number of
companies which address specific segments;
➢ High capital needs, strong and consolidated
companies within the market, existence of patents
and regulation complexity could strongly harm the
entrance of new competitors;
Low   Moderate   High
➢ In general, there is a wide range of suppliers which
cover raw materials and principal components needs,
implying lower bargaining power;
➢ However, some specific materials only provided by
few suppliers (Elekta’s MRI) increase their power;
➢ Prevalence of long-term contracts allied with high
customization pattern enhances the importance of
negotiation. Usually, the manufacturers have to adjust
the given solution in order to fulfill the customer
needs;
➢ High investment in R&D could imply short product
life-cycles, however long-term contracts secure
customer loyalty, thus diminishing this threat.
Papers, peer reviews and clinical data are
important to attract customers
Supremacy of service revenues as
companies try to maximize clients’ loyalty
and recurrent revenues by ensuring
maintenance and support services
Notes: 1) More competitors’ characteristics on Appendix XIII and XIV
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o Elekta is a key player of cancer treatment
equipment distinguished by its efficiency
o The company has reached leading position in
China and strong market share positions in
Americas (21%), EMEA (43%) and Asia
Pacific (40%)
Strong Cash-Flow Generation
Brand Prestige and Market Leadership
o Free Cash Flow generated by the company has
been stable over the past few years
o Moreover, Cash Flow from Operating Activities
has ranged in the last three years between SEK
1000M and SEK 2400M
INVESTMENT THESIS| DEAL RATIONALE & VALUE CREATION STRATEGIES
o Elekta’s history is highly influenced by strategic
acquisitions that have allowed Elekta to widen
its portfolio, differentiate its products from the















Sizeable and Growing Market
o Optimistic radiotherapy industry growth
prospects over the next 5 years, since cancer
incidence is increasing all over the world, with
most markets currently underserved
o Governments are willing to allocate more money
in cancer care, as well as private sector
Accelerating Market Growth 
o MR-Linear Accelerators are set to continue to revolutionize radiotherapy. Therefore,
this market is expected to grow 20% a year. Elekta AB, being the major player in this
segment is well positioned to capitalize on this growth. Moreover, Elekta’s investment
in R&D will be key to consolidate its market position, by offering customized products
that are a key competitive advantage
o MEA and APAC markets are currently underserved, and the trend does not favour
them, since both will have the higher growths of cancer incidence (%) until 2040. This
creates an opportunity for ELEKTA to expand and consolidate its leadership
position in these regions: by taking advantage of its current brand reputation and by
leveraging its geographic presence through the acquisition of an APAC distributor
o Elekta will try to consolidate its position in the remaining markets. The South American
market is currently underserved, but its political and economical unstable climate are

























o Leverage competitive position by acquiring consolidated companies that broaden
Elekta’s product portfolio and are also in line the company’s high standard of precision
and efficiency. In line with internationalization, the acquisition of strategic distributors
will play a key role in Elekta’s short-term strategy. The company might also acquire





o Enhance transformation program pillars and exploit further improvement opportunities.
Continue investment in R&D, reduce COGS and SG&A by leveraging on digitalization
initiatives (remote services, cloud computing) and consolidate lower-cost
manufacturing solutions (replicate Harmony’s cost structure)
Software Distributors Proton Solutions
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Sources: Interview with Investor Relations
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Elekta has a variety of compelling value creation strategies that can enhance its key player position 
Founded in 2003, Micropos develops medical
devices for high precision 4D therapy. The
company manufactures an accessory for radiation
therapy machines to increase the precision and
efficiency of prostate cancer treatment.
Elekta would try to expand the 4D functionalities to
other types of cancers and leverage
hypofractionation (more precision, treatment in




































Notes:; 1) Not included in Investment Case
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Elekta’s Buy & Build targets will contribute to strengthen Elekta’s position
Sources: HCG, IBA and Micropos’ websites, Reuters
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IBA (Ion Beam Applications) was founded in 1986,
from the Catholic University of Louvain-la-Neuve’s
Cyclotron Research Center (Belgium). Although its
primary emphasis started to be medical imaging, the
company moved its focus to proton therapy.
By acquiring one of the key players in the proton
therapy segment, Elekta will be well positioned to
capitalize on the proton therapy market’s growth
and consolidate its position as a global leader in the
radiotherapy segment.
Founded in 1989, Healthcare Global Enterprises is
one of the largest cancer care provider in India,
having a network of over 20 cancer centers spread
across India. Currently employs almost 6,000
people.
The acquisition of Healthcare Global Enterprises is
a major opportunity for Elekta’s expansion in
India and Africa, as it is a key distributor in the
market, since it already operates in both locations,
enhancing Elekta’s internationalization strategy.
Sales growth (proton solutions contributing with 23%);
Expand Elekta’s portfolio to cover all segments
radiotherapy market;
Increase worldwide proton market share.
Sales growth (across all Elekta’s product
portfolio);
Strengthen competitive position in APAC and
in Africa regions (more predominance in APAC).
Implement this feature in Elekta´s different
solutions portfolio in a medium/long term
perspective – apply to different cancers.






































The financials compromise the success of this
acquisition thus it was excluded from our forecast.
Free Cash Flow (M SEK) 2018 2019 2020 2021F 2022F 2023F 2024F 2025F CAGR 
20-25F
EBITDA 2,520 2,616 2,921 3,088 4,445 5,449 6,065 6,778 18.3%
Adjustments:
Change in Net Working Capital 1,665 -265 -1,212 218 -542 -920 -117 -216
Tax -203 -197 -184 -203 -409 -514 -574 -659
Maintenance Capex -816 -659 -762 -1,759 -2,238 -2,764 -3,116 -3,488
%revenues -7.1% -4.9% -5.2% -11.9% -9.9% -10.1% -10.5% -10.8%
Acquisition Capex - - - - -3371 -1943 - -
Cash flow before financing 
(Free cash flow - FCF)
3,166 1,495 763 1,345 (2,115) (693) 2,258 2,415 25.9%
%Growth (53%) (49%) 76% (257%) 67% 426% 7%
FCF (excl. acquisition 
capex)
3,166 1,495 763 1,3445 1,256 1,250 2,258 2,415 
• FCF excluding acquisition capex strengthens from
2020 to 2025 – growing at a CAGR of 25.9% and
reaching SEK 2,415M at exit. In 2022F and 2023F it
decreased, mainly attributable to the acquisitions of
IBA and HCG and variations of change in NWC;
o Elekta’s EBITDA will increase from SEK 2,921M in
2020 to SEK 6,778M in 2025, corresponding to a
CAGR of 18.3%. Its main drivers were HCG and
IBA acquisitions and organic growth;
BUSINESS PLAN | FINANCIALS FORECAST – FREE CASH FLOW
Robust cash flow generation driven by a solid EBITDA growth 
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FCF vs FCF excl Acquisition CAPEX FCF Breakdown
6
• Change in NWC will be positive in 2021F mainly
because of Covid-19 effects (increased average
payable/collection period). From this point onwards
it will come back to 2019 and 2020 values (being
less variable than it used to be);
2
• Tax includes tax shields from D&A and deductible
interest expenses assuming a 24% income tax.
3
• The acquisition of IBA and HCG in 2022F and
2023F respectively, represents a considerable cash















2018 2019 2020 2021F 2022F 2023F 2024F 2025F
Cash flow before financing (Free cash flow - FCF)










 EBITDA Change in NWC CAPEX FCF
• Maintenance Capex will range between 10-12% of
revenues based on forecasted Total Fixed Assets
and acquisitions of IBA and HCG.
4
4
o The Gross Profit can be divided
into revenues growth and gross
margin improvement;
o Revenues will increase over the
investment period from 14,601M to
32,408M due to the implementation of
the value creation strategies, leading
to an impact of 3,562 in EBITDA;
o Gross margin will improve from
42.6% (2020) to 44.6% (2025) due to
economies of scale and the
acquisition of HCG, leading to an
impact of 633M in EBITDA.
BUSINESS PLAN | FINANCIALS FORECAST – EBITDA BRIDGE
EBITDA will double until 2025 due to an increase of revenues and improvement of margins
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o The Covid-19 pandemic enhanced a
continuation of operational
improvements (digitalization, reduction
of travelling) that will drive the
reduction of these costs’ weights on
revenues;
o The integration of HCG and IBA will
somewhat offset these improvements,
as both companies have lower margins,
compared to ELEKTA, leading to a
negative impact of EBITDA margin of
338M.
EBITDA GROWTH DRIVERS1
Gross Profit EBITDA Margin
EBITDA GROWTH BRIDGE
Organic Growth
o Elekta will continue to develop
and enhance all its radiotherapy
solutions, however, MR-Linacs
and OIS will have the most
significant growths, as their
respective markets will increase
significantly over the next years;
o As a result, organic growth will
add SEK 1,272M to Elekta’s
EBITDA.
o As the market leader of proton
therapy, IBA is expected to
contribute with an additional SEK
1,542M to Elekta’s EBITDA over
four years, helping Elekta consolidate
its position as a leader in
radiotherapy.
o The acquisition of HCG will help
Elekta boost its revenues in all its
radiotherapy solutions in APAC and
some African regions. Consequently, it
is projected that Elekta’s EBITDA is
increased by SEK 1,044M.
IBA & HCG 
MSEK MSEK
BUSINESS PLAN | MANAGEMENT PACKAGE
MANAGEMENT PACKAGE
Management incentive package contains sweet equity, a bonus payment and a PSU’S plan
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PSU'S PLAN 2021E 2022E 2023E 2024E 2025E
% of sweet equity 0.50% 0.50% 0.75% 0.75% 1%
If Gross Profit and EBITDA are met at 100%
Gustaf Salford 0.27% 0.27% 0.40% 0.40% 0.54%
Johan Adebäck 0.11% 0.11% 0.16% 0.16% 0.21%
Paul Bergström 0.06% 0.06% 0.10% 0.10% 0.13%
Jonas Bolander 0.06% 0.06% 0.10% 0.10% 0.13%
If Gross Profit and EBITDA are met at 85%
Gustaf Salford 0.16% 0.16% 0.24% 0.24% 0.32%
Johan Adebäck 0.06% 0.06% 0.10% 0.10% 0.13%
Paul Bergström 0.04% 0.04% 0.06% 0.06% 0.08%
Jonas Bolander 0.04% 0.04% 0.06% 0.06% 0.08%
VESTING RULES 2021E 2022E 2023E 2024E 2025E
Final Sweet Equity Stake 15.0%
% Sweet Equity Vested 
per year
10% 25% 40% 80% 100%
Vested Equity Stake 1.50% 3.75% 6.00% 12.00% 15.00%
Management proceeds 74 658 1,638 4,175 6,681
Gustaf Salford 43 383 954 2431 3890
Johan Adebäck 14 125 311 793 1269
Paul Bergström 8 75 187 476 761
Jonas Bolander 8 75 187 476 761
PSU’S PLAN
A long-term incentive based on performance-vested shares contingent
upon achieving EBITDA and Gross Profit annual levels. The promised number
of shares are in line with the additional % of sweet equity defined on the
table to the right and will be split across management considering their entry
equity - if MM is lower than 2.50x they will not be rewarded.
3
Total Remuneration Bonus Payment
Gustaf Salford 15027 2216                                                 
Johan Adebäck 4901 875                                                
Paul Bergström 2940 525                                              
Jonas Bolander 2940 525                                                
TOTAL 25809 4141
In 2021, an immediate bonus payment will be paid to management, equal to
25% of their fixed annual salary amount. This payment will leverage
management’s motivation in the current pandemic context.
BONUS PAYMENT 2
25%
PARTICIPATION IN SWEET EQUITY
Managers will be required to invest twice its total annual salary in exchange
for a 15% equity stake which will be vested accordingly with the table.
The four members of the management team will have different equity stakes
(accordingly with their salaries and positions):
1
• Gustaf Salford will invest SEK 30.05M and receive 58% of sweet equity;
• Johan Adebäck will invest SEK 9.80M and receive 19% of sweet equity;
• Paul Bergström and Jonas Bolander will invest SEK 5.88M each and 













EXIT & RETURNS | ENTRY MULTIPLE
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ENTERPRISE VALUE (M SEK)
DCF – EXIT MULTIPLE METHOD
o This DCF is based on a EV/EBITDA multiple
of 13.13x used to compute the terminal value.
o To discount the FCF, it was used a WACC of
6.64%, which is decomposed on Appendix X
o This valuation was not included in the final




o Considering the same list of 6 comparables, a
valuation through one-year forward
EV/EBITDA multiples was computed, arriving




DCF – GORDON’S GROWTH
o The DCF using Gordon’s growth model was
performed with a terminal growth rate (TGR)
of 2.5% (in line with market prospects – e.g.
increase of cancer incidence).
o It was not included in the final EV as it is
mainly explained by the terminal value




o Considering a qualitative and quantitative
analysis (i.e. similar EBITDA margin and capital
structure) it was possible to list 6 comparables.
o Using one-year forward P/E multiples, the
minimum value was 22.71x while the




o This valuation methodology was computed
based on past transactions in the cancer
care industry.
o It was possible to verify that there is recurring
discrepancies in the multiples’ value, ranging




o A 10-year cycle adjustment was made for
both multiples used in the comparables
analysis to eliminate one-time events.
o In general, there has been a multiples’






Considering different methodologies, an EV/EBITDA of 13.13x and an EV of SEK 38,339M was arrived
Sources and Uses of Funds:
Sources of Funds
▪ They are distributed between Debt (5x EBITDA – 14,605M) and Equity (8.8x EBITDA – 25,651 M);
▪ Total Debt is allocated among two tranches (A and B) - Term A amortized senior Debt of 2,921M – 1x
EBITDA and Term B bullet payment senior Debt of 11,684M – 4x EBITDA.
▪ Equity is divided in FRI (25,307M – 8.7x EBITDA) and Ordinary Equity (344M – 0.1x EBITDA).
Uses of Funds
▪ Total Uses of funds corresponds to SEK 40,256M, distributed into EV (38,339M – 95%) and Fees
(1,917M – 5%);
Scenarios – Capital Structure:
▪ Scenario 1 was chosen in favor of number 2 and 3, as it constitutes a more conservative approach
(better Cash Cover, Interest Coverage and Debt/EBITDA), without compromising the minimum
threshold of the investor’s returns. In comparison with scenario 9, scenario 1 was chosen because it
presents better returns for investors.
EXIT & RETURNS | CAPITAL STRUCTURE (2/2)
Sources of funds will be composed of 63.7% equity and 36.3% debt
























SOURCES & USES OF FUNDS1



















SCENARIOS – CAPITAL STRUCTURE
FINAL RATIONALE
Notes:1) Including cash overfunding – used on acquisitions
SCENARIOS 1 2 3 9
Leverage 5.0x 6.0x 5.5x 4.5x
IRR 24.00% 25.74% 24.83% 23.23%
MM 2.93x 3.14x 3.03x 2.84x
Cash Cover
SCENARIOS Term A Term B Term C 2021 2022 2023 2024 2025
1 1.0x 4.0x 0.0x 1.4x 1.5x 1.5x 2.1x 2.3x
2 1.0x 5.0x 0.0x 1.2x 1.4x 1.4x 1.9x 2.1x
3 1.0x 4.5x 0.0x 1.3x 1.4x 1.5x 2.0x 2.2x
9 1.0x 3.5x 0.0x 1.4x 1.6x 1.6x 2.2x 2.4x
EXIT & RETURNS| EXIT WATERFALL & CREDIT STATISTICS
The fund’s investors will have a return of 3.14x, corresponding to an IRR of 25.7% 
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EXIT WATERFALL BRIDGE
MSEK
The presented credit statistics imply that all covenants will be respected
(computed via conservative bank case) under the predicted investment case
scenario. Specifically, Cash Cover (excluding acquisitions) and Interest Cover will
start with 1.4x and 7.2x multiple, respectively, and will increase over the investment
period as the firm is more capable of paying debt obligations. Debt/EBITDA will start
at 4.6x in 2021 and will decrease to 1.8x at the year of exit due to Term Loan A
amortization and EBITDA increase. The cash amount was excluded from this analysis
since its value is abnormal due to overfunding.
Summary Credit Stats 2021F 2022F 2023F 2024F 2025F
Cash Cover 1.4x 1.5x 1.5x 2.1x 2.3x
Cash Covenant 1.0x 1.0x 1.0x 1.0x 1.0x
Interest Cover 7.2x 10.3x 11.9x 13.5x 16.5x
Interest Covenant 6.4x 7.5x 8.7x 9.4x 10.8x
Debt / EBITDA 4.6x 3.1x 2.5x 2.1x 1.8x
Leverage Covenant 5.1x 4.5x 3.8x 3.4x 3.0x
CREDIT STATISTICS
In 2025, management receives proceeds of SEK 6,681M, corresponding
to a MM of 129.4x and an IRR of 164.5% (PSU Plan included);
Institutional investors receive, in the exit year (2025), SEK 75,037M,
which translates in a return of 2.93x (MM) and an IRR of 24.0%
Returns 2021F 2022F 2023F 2024F 2025F
Management Exit 
Proceeds
74 658 1,638 4,175 6,681
Management Entry Equity 52 52 52 52 52




32,491 45,842 56,384 65,139 75,037
Institutional Investor 
Equity
25,599 25,599 25,599 25,599 25,599
Institutional Returns 1.27x 1.79x 2.20x 2.54x 2.93x
IRR 24.0%
In 2025, a combined value (EV + Cash) of SEK 94,132M will be distributed into debt
repayments, investors and managers. At exit, debt value will be SEK 12,414M, since it
is still left to repay SEK 730M of Term Loan A (amortized over 6 years) and the total of
Term Loan B (because it is amortized only at year seven).
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STRATEGIC SALE IPOSECONDARY SALE
EXIT OPTIONS & DUE DILIGENCE | EXIT OPTIONS & TARGET BUYERS
A strategic sale implies that another major player







More expensive process – High
transaction costs (e.g. underwriter fees are
the largest)
Access to capital markets, increasing
significantly the number of potential buyers
comparing with the other exit solutions.
Because such acquisition would bring
benefits for the acquirer (i.e., synergies), it
is likely that the transaction value would
include a premium, increasing the returns
for the fund;
The feasibility of this option is highly
dependent on finding a suitable target
acquirer. In this particular case, because
Elekta AB is one of the biggest players in
radiotherapy, a target buyer would
probably have to come from another
sector closely related to radiotherapy;
Moreover, a strategic sale is usually slower
than a secondary sale. Furthermore, strategic
sales are losing popularity in this sector,
having decreased from 40% to 33% in 2018.
In the last years, PE exit through IPO’s in
healthcare industry were mainly linked to
biopharma smaller-stage companies.
It has become more frequent following the PE
sector increasing trend. The Exit Value of
Healthcare PE industry increased in 2019 to
$40.8B, compared with $31.6B in 2018,
moreover, secondary sale transactions
represented 53% in 2019;
ELEKTA is an attractive buyout target –
healthy CF and room to become the market
leader of radiotherapy industry (high growth
potential);
Industry’s strong returns allied and
resilience at any stage of the economic
cycle. In addition, this strategy is faster than
the alternatives;
Increasing interest from strategic buyers
lead to higher entry valuations which are
unattractive to potential PE buyouts;
Dependent on market conditions and
specific timings that could harm fund’s exit
and returns.
Sources: Bain & Company Report “Healthcare Exits”
Typically, the fund is not able to sell all 
its equity position, thus increasing the 
overall risk of the exit (i.e. subject to post-
IPO market reaction and loss of control)
INDIVIDUAL SECTION
BUSINESS PLAN | FINANCIALS FORECAST – ORGANIC VS INORGANIC REVENUES
Inorganic sales will have an important role on achieving forecasted profitability levels
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
Sources: Elekta’s Annual Report
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MR – Linac segment will grow at a CAGR of 29.73%, empowered by a
rise in demand for MRI technology and by Elekta’s ability to capitalize on
this;
Linacs’ revenues will increase more than SEK 2,000M, mostly due to the
closing of the gap of Linacs shortage in countries where Elekta is
already presented (i.e. most APAC countries) and replacement of old
equipment;
OIS’ revenues will more than double in only five years, as information
solutions are becoming more and more relevant in the oncology market.
Elekta will continue to develop OIS reinforcing its bet on innovative and
customized solutions that drive the fight against cancer forward;
Internationalization (through existent distribution channels) and quality
aftermarket services will also enhance Elekta’s revenues among all
segments.
ORGANIC GROWTH DRIVERS INORGANIC GROWTH DRIVERS
o Acquisition of IBA will add SEK 3,134M of revenues in Proton Solutions in
2021/22. The market for proton therapy has been growing and it is expected
that this acquisition will be a significant factor for Elekta’s success;
o By acquiring HCG, Elekta’s revenues will rise in all segments with a particular
focus on Linacs, MR-Linacs, OIS and Proton Solutions, specially by increasing
its presence in India, China and Africa;
o Not only that, but also there will be synergies from both acquisitions, as
IBA’s strategy will change to be more focused on proton solutions, and
HCG’s direct relationship with Elekta will be a key competitive advantage








2021F 2022F 2023F 2024F 2025F
Organic Growth vs Inorganic Growth




























2021F 2022F 2023F 2024F 2025F 2026F 2027F
Organic vs Inorganic  Revenues
Organic Sales Inorganic Sales
2
Revenue Breakdown 2018 2019 2020 2021F 2022F 2023F 2024F 2025F
CAGR  
20-25
SOLUTIONS 7,054 8,392 8,845 8,779 13,359 15,954 17,077 18,282 15.63%
MR-Linac -
252 354 381 540 1,040 1,170 1,300 30%
Linac 4,585 5,371 5,572 5,294 6,130 7,430 7,523 7,894 7%
Brachytherapy 564 629 663 694 726 770 794 831 5%
Neuro Solutions 917 923 929 969 1,008 1,026 1,040 1,092 3%
OIS 988 1,217 1,327 1,441 1,821 2,386 2,663 3,021 18%
Proton Solutions - - - -
3,134 3,302 3,887 4,144 10%
SERVICES 4,519 5,163 5,756 5,943 9,282 11,456 12,721 14,127 19.67%
TOTAL REVENUES 11,573 13,555 14,601 14,722 22,640 27,410 29,798 32,408 17.29%














BUSINESS PLAN | FINANCIALS FORECAST - REVENUES
Revenues will more than double until 2025, mainly driven by Linacs, MR-Linac and Proton Solutions
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Sources: Elekta’s Annual Report
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Notes: 1) M&A strategy’s revenues are SEK 6,018M in 2025 (4,144M – proton therapy; 1,874M – distributed among the remaining solutions). 
M SEK
o The acquisition of HCG in 2023, will drive the
revenues forward (mostly, not exclusively, MR-Linacs
and Linacs), in APAC and Africa, adding more than
SEK 5,000M in three years to Elekta’s revenue;
1
o The demand for MR-Linacs is expected to grow
significantly, as its image-guidance feature is a
breakthrough innovation in the market. Elekta, being
the market leader in this segment, possessing the
infrastructure to increase its production, the
agreement with ViewRay and the purchase of HCG,
will boost its revenues at a CAGR of around 30%;
2
o The global shortage of Linacs’ supply, emergent
markets in APAC and MEA, a constant need for
equipment replacement and the acquisition of HCG
are opportunities that Elekta will seize, growing at a
CAGR of 7.21% in this segment.
3
o Neuro Solutions and Brachytherapy will lose
importance in Elekta’s portfolio due to a shift in
prioritized segments. On the other hand, OIS will
grow;
4
o The acquisition of IBA in 2022 will generate SEK
14,500 M of revenues in four years, from proton







EXPENSES (MSEK) 2018 2019 2020 2021F 2022F 2023F 2024F 2025F
CAGR 
20-25
Cost of products sold -6,465 -7,829 -8,379 -8,392 -12,958 -15,367 -16,606 -17,965
(% revenues) 55.9% 57.8% 57.4% 57.0% 56.5% 56.0% 55.6% 55.3%
Gross Profit 5,108 5,726 6,222 6,331 9,683 12,043 13,191 14,443 18.3%
Gross Margin (%) 44.1% 42.2% 42.6% 43.0% 42.8% 43.9% 44.3% 44.6%
Selling expenses -1,071 -1,164 -1,290 -1,266 -1,861 -2,688 -2,874 -3,064
Administrative 
expenses 
-887 -974 -843 -854 -1,470 -1,666 -1,804 -1,940
R&D expenses -671 -892 -871 -957 -1,630 -1,908 -2,085 -2,266
Operational Costs (%) 22.7% 22.4% 20.6% 20.9% 21.9% 22.8% 22.7% 22.4%
EBITDA 2,520 2,616 2,921 3,088 4,445 5,449 6,065 6,778 18.3%
EBITDA Margin (%) 21.8% 19.3% 20.0% 21.0% 19.6% 19.9% 20.4% 20.9%
o R&D investment (without D&A) will stabilize at 7% of
sales. This value is a consequence of the R&D
investments that Elekta and IBA must make, offset
by HCG’s lack of need to invest in R&D.
o SG&A (both without D&A) will move in different
directions. Even though Elekta’s digitalization and
transformation program will decrease its weights
internally (% revenues), the acquisition of HCG will
contribute to an increase of selling expenses from
2023 ownwards. Regarding administrative
expenses, they will stabilize at 6.0%, as both HCG
and IBA do not have significant related expenses as
well;
o Elekta’s gross margin is expected to reach 44.6% in
2025. Since IBA has lower margins, Elekta’s total
gross margin will decrease in 2022F - acquisition
year. This will be offset by the optimization of
manufacturing processes in Elekta (mainly in MR-
Linacs and Linacs), the acquisition of HCG (which
has better margins than Elekta) and the





BUSINESS PLAN | FINANCIALS FORECAST - EBITDA
EBITDA margin will increase, despite some fluctuations driven by lower EBITDA margin acquisitions  
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Sources: Elekta’s Annual Report
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2018 2019 2020 2021F 2022F 2023F 2024F 2025F
Operating Costs vs EBITDA Margin
COGS SG&A R&D EBITDA Margin (%)
COMPARABLE PRIVATE EQUITY DEALS 
MAIN OUTPUTS ELEKTA
EXIT & RETURNS | CAPITAL STRUCTURE (1/2)
Past private equity deals in the healthcare sector were studied to project Elekta’s debt structure
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CURRENCY | INDEX TERM A TERM B
REVOLVER 
(WC needs)
SIZE (M) bps SIZE bps SIZE bps
CINVEN SEBIA SA 800 340 42.50% N/A N/A EUR | EURIBOR 3M 70 425 250 500 20 425
CINVEN SYNLAB HOLDING 1200 250 20.83% 6.60x BB+ EUR | EURIBOR 3M - - - - 250 300
BAIN CAPITAL 
PARTNERS
RENAL ADVANTAGE 850 415 48.82% 3.70x B+ USD | USD LIBOR 3M - - 365 425 50 425
EQT DELLNER COUPLERS 809 360 44.50% 5.00x N/A EUR | EURIBOR 3M - - 240 400 120 N/A
GOLDMAN SACHS (PE) ICON CANCER CARE N/A 370 N/A 4.50x B+ AUD | BBSW 3M 93 400 278 425 - -








From these main outputs, it is possible to make some assumptions regarding





EURIBOR + 375 bps
EURIBOR + 425 bps
Term A has seniority
over Term B
From the displayed list above, which mainly includes private equity deals of
healthcare companies (but not perfect comparables of Elekta), it is possible to
conclude that:
Debt to Transaction Value is usually around 40%
Leverage multiple ranges between 4.0x and 6.5x EBITDA
Credit rating of the transactions averaged B+ or BB+
Loans were priced with a spread between 300 to 500 bps over a 3 months 
LIBOR/EURIBOR rate
Most predominant tranche used is the Term B bullet payment loan, followed 
by smaller tranches of Term A and Revolver.
Conservative leverage
on Bank Case1
Note: 1) This approach is in line with the sector’s conservative trend and the COVID crisis. The value of 6.0x is a future possibility, since it corresponds to the estimated maximum leverage on Bank Case.
EXIT & RETURNS| VALUE CREATION
In 5 years, the investment will generate SEK 56,067M through Cash Generation and EBITDA growth
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o The value of entry equity will be
SEK 25,651M, which will be
distributed into Fixed Return
Instruments and Ordinary Equity;
o Fixed Return Instruments will be
valued SEK 25,307M at entry,
while Ordinary Equity will be
valued at SEK 344M. In total,
Entry Equity will correspond to
63.7% of Total Sources;
o Fees are expected to cost SEK
1,917M, conforming 5% of
Elekta’s Enterprise Value.
Entry Equity + Fees
DRIVERS
Revenue and EBITDA Margin Exit Equity
VALUE CREATION
o Revenue growth and EBITDA margin
improvement will be the main drivers
of value creation;
o In line with the Investment Thesis,
revenues will grow due to the Buy &
Build and Internationalization
strategies, creating SEK 46,757M of
value;
o EBITDA margin will improve by
0.9%, as a result of the operational
improvements that are intended to
be implemented, generating SEK
3,872M in value.
o As a result of these drivers, the value
of equity at exit will be SEK 81,718M,
corresponding to a total value
creation of SEK 56,067M over five
years;
o This value of exit equity will be
divided into Fixed Return Instruments
and Ordinary Equity (as it will be
possible to see in the next slide);
o With a value of net debt at SEK
7,251M, Elekta’s enterprise value
(excluding cash) will be SEK
88,968M.
o The entry debt will be SEK 14,605M
(accounting for the remaining 36.3%
of Total sources) divided into Term
Loan A and B, which will be
amortized for six years and at the
seventh year respectively;
o This amortization will generate SEK
7,354M of value through cash
generation, as the value of net debt
at exit will be SEK 7,251M;










Equity 25,651 -1,917 7,354 50,629 0 81,718
MM 1.00x -0.07x 0.29x 1.97x 0.00x 3.19x
IRR 26.08%
The IRR of this investment is projected to be 26.08%, corresponding
to a combined (investors + management ) MM of 3.19x.
▪ A sensitivity analysis (on the MM and IRR) was made for different scenarios: the base scenario, which evaluates the impact of changing the Exit Multiple
(between 25% and 75% quartiles) and Exit Year; a scenario without IBA’s acquisition; and a scenario where the projected revenue growth is changed;
▪ Regarding the base scenario, it is possible to conclude that IRR and MM are inversely correlated as the Exit Year distances itself (IRR decreases, MM increases),
even though they are positively correlated in the same year. Also, the impact of increasing Exit Multiple on IRR is diluted as Exit Year moves forward;
▪ Without IBA’s acquisition, returns decrease significantly, reaching values below the threshold of 2.5x-3-0x and, consequently, an IRR smaller than 20%-25% target;
▪ In the last scenario, returns are slightly sensitive to changes in revenue growth. Nevertheless, if the exit year is still 2025, a decrease in 2% of the revenue
growth would not compromise the threshold of 20%-25% (IRR) – the threshold would not be respected only if decrease is higher than 3.5%.
EXIT & RETURNS| SENSITIVITY ANALYSIS
In most of the scenarios, returns threshold is verified but sensitive to exit year and exit multiple 










MM 2023F 2024F 2025F 2026F 2027F
11.07x 1.60x 1.83x 2.08x 2.36x 2.64x
11.70x 1.69x 1.93x 2.19x 2.48x 2.77x
12.30x 1.77x 2.02x 2.29x 2.59x 2.89x
13.13x 1.89x 2.15x 2.43x 2.75x 3.06x
14.30x 2.06x 2.34x 2.64x 2.97x 3.30x
15.60x 2.25x 2.54x 2.86x 3.22x 3.57x










IRR 2023F 2024F 2025F 2026F 2027F
11.07x 17% 16% 16% 15% 15%
11.70x 19% 18% 17% 16% 16%
12.30x 21% 19% 18% 17% 16%
13.13x 24% 21% 19.5% 18% 17%
14.30x 27% 24% 21% 20% 19%
15.60x 31% 26% 23% 21% 20%
16.89x 35% 29% 25% 23% 21%











MM 2023F 2024F 2025F 2026F 2027F
11.07x 1.84x 2.14x 2.49x 2.83x 3.17x
11.70x 1.95x 2.27x 2.62x 2.98x 3.33x
12.30x 2.06x 2.38x 2.75x 3.12x 3.48x
13.13x 2.20x 2.54x 2.93x 3.31x 3.69x
14.30x 2.41x 2.77x 3.18x 3.59x 3.99x
15.60x 2.64x 3.03x 3.47x 3.90x 4.33x










IRR 2023F 2024F 2025F 2026F 2027F
11.07x 23% 21% 20% 19% 18%
11.70x 25% 23% 21% 20% 19%
12.30x 27% 24% 22% 21% 20%
13.13x 30% 26% 24.0% 22% 21%
14.30x 34% 29% 26% 24% 22%
15.60x 38% 32% 28% 25% 23%






















MM 2023F 2024F 2025F 2026F 2027F
-2% 2.09x 2.37x 2.69x 2.99x 3.28x
-1% 2.14x 2.46x 2.81x 3.15x 3.48x
0% 2.20x 2.54x 2.93x 3.31x 3.69x
1% 2.26x 2.64x 3.06x 3.49x 3.92x





















IRR 2023F 2024F 2025F 2026F 2027F
-2% 28% 24% 22% 20% 19%
-1% 29% 25% 23% 21% 20%
0% 30% 26% 24% 22% 21%
1% 31% 27% 25% 23% 22%
2% 32% 29% 26% 24% 23%
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Goldman Sachs and KKR are the more appropriate sponsors for secondary sale
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SECONDARY SALE

































As growth equity investors, General
Atlantic seems to be not a potential
buyer for Elekta in 2025F as there
should not be potential for dramatic
growth/changes in lifecycle.
Founded in 1980, General Atlantic is
a PE firm based in New York that
pioneered the concept of growth
equity. The company has positions in
14 global locations covered by 183
investment professionals.
Founded in 1994, EQT is the
largest Private Equity firm in
Nordic Europe. It invests in mid
and large cap companies in a
variety of sectors and regions. It
has invested more than € 62B.
Founded in 1976, KKR is a PE firm based
in New York. It invests in all industries and
may also co-invest. It is attracted by





































Even though EQT has made
considerable investments in the
healthcare sector in Sweden, it
does not usually invest more than







For around 30 years, Goldman Sachs
has been investing in Private Equity
Deals through the “Goldman Sachs
Merchant Banking Division”, making
them a leading private equity firm
globally.
KKR is a leading PE firm with sufficient
capital and know-how to create value and
consolidate ELEKTA’s position. They are
disciplined investors, focused on long-term
business fundamentals that partner with
public companies to leverage industry
expertise with operational capabilities.
Being one of largest private equity
firms, Goldman Sachs has the capital
to buy Elekta AB and the know-how
to continue to strengthen Elekta’s
strong position in the radiotherapy
Consumer Healthcare







Sources: Goldman Sachs, KKR, General Atlantic and EQT’s websites
Confidence 
Level High
Notes: 1) Values in parentheses () correspond to ongoing deals
Nova School of Business and Economics | Private Equity Challenge: ELEKTA AB | January 2021 
Commercial, financial and legal analysis are key to confirm transaction’ feasibility
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DETERMINANT ASPECTS TO ANALYZE POSSIBLE OUTCOMES
(1) Financial Statements – In depth analysis of cash flow drivers (i.e. NWC,
maintenance CAPEX) in the historical performance and confirm whether the forecast
of this captions was correctly inferred.
(2) Lack of data - Assess the accuracy and solve lack of data given by Elekta on
important captions (e.g. profitability for each type of products and customers)
ASSESSMENT
(1) R&D – Assess the level of R&D needed in the MR-Linac segment and study the R&D
investment of close competitors
(2) Value Chain – Determine the dependence on specific suppliers and check if suppliers
can meet increasing demand
(3) Cost Structure – Determine the possibility of replicating Harmony’s cost structure into
other products and the feasibility of economies of scale in MR-Linacs’ production
(1) Lose capacity to capitalize on MR-Linac’s market
growth and fail market consolidation.
(2) Inability to increase production and implement
internationalization
(3) Inability to increase Gross Margin
(1) COVID-19 – Study the probability and effects of restriction measures that negatively
impact the access for cancer treatments
(1) Decrease in demand for new radiotherapies solutions
in the short-term
(1) NWC and Maintenance Capex estimation could be
skewed, thus affecting the overall LBO model and
capital structure defined
(2) Forecast drivers could be overestimated (e.g. prices
per solution/service and number of systems)
(1) Potential clients might lose interest in Elekta’s
products if they are not reimbursed & Emerging
markets might not be attractive (cancer treatments
might be expensive for the population)
(2) Possible interdiction of Elekta’s solutions (countries)
(3) Possible suspension of sales of Elekta’s solutions
during adaptation (to new legislation) period
(1) Difficulty to measure realistic synergies, difficult
integration
(2) Possible weak position in neuro and brachy solutions
(3) Overestimation of positive outlook in key markets
(4) Low customers’ satisfaction level could harm defined
expectations
(1) Reimbursements and Payment Models - Check if Elekta’s products are eligible for
reimbursements by insurances and governments’ programs & study the different
payment models for cancer treatment in emerging markets
(2) ESG - Assess if Elekta’s products and manufacturing remain in compliance with each
country’s regulatory policies and follow environmental / ethical rules
(3) Legislation - Study if governments will change significantly their healthcare policy
(1) M&A – Full diligence on acquisition targets: margins, synergies, growth drivers
(2) Competitive Position – Detailed competitors' analysis & Siemens acquisition of Varian
(3) Market Growth & Trends – Analysis of major trends during the next 5 years (special
focus on APAC region, Proton and MR-Linacs Solutions)
(4) Customer Relationship – Deep analysis of customers’ contracts and its satisfaction
level (reliability, quality, service)
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MASTER THESIS
PRIVATE EQUITY – THE RELEVANCE OF APAC IN THE FUTURE OF THIS AREA 
From the beginning of the PE course / Master Thesis program until now, it has become clear to me that the future of Private Equity might rely on the development of this
area, as well as in its importance in the APAC market. Even though COVID-19 has significantly disturbed the current global PE industry - specially APAC, since it still does
not have a solid and robust PE industry – the APAC market is still seen by many as the market with higher long-term growth prospects.
Since this is an emerging market that is becoming, year after year, more relevant and, at the same time, playing a bigger role, it is necessary to fully understand its
characteristics / trends – Due Diligence – in order for PE funds to succeed / create opportunities to leverage its positions. Notwithstanding, it is very important to
understand the mechanism behind the strong growth of this market prior to COVID-19, and to clarify what might have changed as a result of this pandemic. COVID-19
also helped to decrease firms’ valuations (or at least slow down its increasing trend) and it might have created room for potential multiple arbitrage in the following years.
There are sectors that have reinforced its importance over the past years, like the healthcare – people in APAC started to have access to products (fast food, alcoholic
drinks, cigars) which have deteriorated its healthy lifestyle, thus, leading to a stronger presence and importance of this sector - that can be seized and exploit by PE
firms/funds, since more than 1/3 of the global population is eligible of being a potential customer (vaccines, cancer treatment, health plans, diseases). At the same time, I
think, that by being more dependent on APAC, PE funds would need to establish strategic networks in order to take advantage of its APAC portfolio companies.
Moreover, while researching for the PE Challenge, I found out that countries like China and India are creating more partnerships (e.g. licensing agreements) with foreign
companies from different sectors, in order to modernize and expand its existing infrastructure – ELEKTA AB (PE Challenge) has reached an agreement with both
countries in the last 2 years to license its products’ portfolio, expanding its geographical landscape. Like ELEKTA, there are many other examples of companies that are
exploring the opportunity of “grabbing a slice” of this such important market, delivering high-quality products and services which positively impact IT industry. By letting their
doors open to the world, they are creating opportunities for mature PE funds to capitalize on this positive investment trend.
Consequently, in-house (Chinese, Indian) PE funds will grow in the nearby future and will “fight” for the best opportunities along with the top PE funds that exist nowadays.
For the reasons above-mentioned, I think that the APAC market is the most relevant market for the growth of Private Equity industry.
The Private Equity challenge’s format was, undoubtedly, an enriching experience which allowed me to enlarge my horizon, to gain key analytical skills, and to explore
different perspectives about this fast-pacing, fascinating and incredibly relevant Financing area - being a strong possibility for my future working career.
During the thesis, I constantly applied the key concepts, learned at the PE course, in order to build a Leveraged Buyout model (company/market analysis, business
forecasts, valuation methods, exit & returns, debt structuring scenarios) and an Investment Committee Paper, summarizing all the different above-mentioned subtopics.
This program enabled me to develop specific technical skills, such as analytics, excel modelling, LBO breakdown/returns, due diligence, critical & creative thinking, as
well as to potentialize my soft skills: teamwork, communication, respectfulness, creativity, flexibility and cooperation – which are currently highly valued in the job market.
All in all, it was a great experience, and I am grateful for working with two mind-blowing friends / top future businessmen.
“All in all, it was a great experience, and I am thankful for working with two mind-blowing friends” 
INDIVIDUAL REFLECTION | 41075
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Websites lead the path on finding information about ELEKTA / Radiotherapy Market
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